Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Total Assets of $530.92 million for the year ending 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +42.0% in Total Assets from 2024 to 2025.
- This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $180.62 million | Q3 2018: $172.79 million | Q1 2019: $147.69 million | Q2 2019: $195.44 million | Q3 2019: $177.23 million | Q1 2020: $144.44 million | Q2 2020: $190.73 million | Q3 2020: $174.64 million | Q1 2021: $144.62 million | Q2 2021: $220.38 million | Q3 2021: $206.24 million | Q1 2022: $194.39 million | Q2 2022: $175.12 million | Q3 2022: $164.12 million | Q1 2023: $83.44 million | Q2 2023: $78.64 million | Q3 2023: $192.46 million | Q1 2024: $382.46 million | Q2 2024: $368.96 million | Q3 2024: $354.25 million | Q1 2025: $348.58 million | Q2 2025: $326.08 million | Q3 2025: $577.45 million.
- Over the full 9 years of available data (2017 to 2025), Dianthus Therapeutics, Inc. /DE/'s Total Assets has grown by 874.8%.
- Historical annual values: Fiscal year 2025: $530.92 million | Fiscal year 2024: $374.01 million | Fiscal year 2023: $179.41 million | Fiscal year 2022: $83.11 million | Fiscal year 2021: $189.93 million | Fiscal year 2020: $161.62 million | Fiscal year 2019: $161.51 million | Fiscal year 2018: $157.31 million | Fiscal year 2017: $54.46 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: